Your browser doesn't support javascript.
loading
Epigenetics behind tumor immunology: a mini review.
Musella, Martina; Manduca, Nicoletta; Maccafeo, Ester; Sistigu, Antonella.
Affiliation
  • Musella M; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
  • Manduca N; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
  • Maccafeo E; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
  • Sistigu A; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168, Rome, Italy. antonella.sistigu@unicatt.it.
Oncogene ; 42(39): 2932-2938, 2023 09.
Article in En | MEDLINE | ID: mdl-37604925
Immunogenic- and immune-therapies have become hot spots in the treatment of cancer. Although promising, these strategies are frequently associated with innate or acquired resistance, calling for combined targeting of immune inhibitory signals. Epigenetic therapy is attracting considerable attention as a combination partner for immune-based therapies due to its role in molding the state and fate of cancer and immune cells in the tumor microenvironment. Here, we describe epigenetic dysregulations in cancer, with a particular focus on those related to innate immune signaling and Type I interferons, and emphasize opportunities and current efforts to translate this knowledge into treatment regimens with improved clinical benefit.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Interferon Type I / Neoplasms Limits: Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Interferon Type I / Neoplasms Limits: Humans Language: En Year: 2023 Type: Article